Clinical Trials
42
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
- Conditions
- Gliomas Harboring IDH1 and/or IDH2 Mutations
- Interventions
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 52
- Registration Number
- NCT07025018
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
- Conditions
- Mass Balance Study
- Interventions
- Drug: 100 µCi [14C] HMPL-306
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 6
- Registration Number
- NCT06671873
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, China
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: HMPL-760 planned dose 1Drug: R-GemOxDrug: HMPL-760 placebo planned dose 1Drug: HMPL-760 planned dose 2Drug: HMPL-760 placebo planned dose 2
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 61
- Registration Number
- NCT06601504
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 412
- Registration Number
- NCT06584032
- Locations
- 🇨🇳
Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 132
- Registration Number
- NCT06387082
- Locations
- 🇨🇳
Tianjin People's Hospital, Tianjin, China
🇨🇳Wuhan Union Hospital of China, Wuhan, China
🇨🇳Xiangya Hospital of Central South University, Changsha, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
Inmagene Initiates Phase 2b Trial of IMG-007 Anti-OX40 Antibody for Moderate-to-Severe Atopic Dermatitis
Inmagene Biopharmaceuticals has dosed the first patient in its ADAPTIVE Phase 2b trial evaluating IMG-007, a non-depleting anti-OX40 monoclonal antibody, for moderate-to-severe atopic dermatitis treatment.
China Approves ORPATHYS-TAGRISSO Combination for EGFR-Mutated Lung Cancer with MET Amplification
China's National Medical Products Administration approved the ORPATHYS-TAGRISSO combination for treating EGFR-mutated non-small cell lung cancer patients with MET amplification after disease progression on EGFR inhibitor therapy.
AstraZeneca Showcases Groundbreaking Cancer Research at ASCO 2025 with Two Plenary Presentations
AstraZeneca will present over 80 abstracts at ASCO 2025, including two plenary presentations featuring camizestrant for HR-positive breast cancer and IMFINZI for early gastric cancer, marking their seventh consecutive year with plenary data.
Global Thrombocytopenia Clinical Trials Market Sees Significant Growth in 2025
The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis.
Over 220 Pipeline Therapies in Development for Non-Hodgkin's Lymphoma, Reports DelveInsight
DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.
China's NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant Follicular Lymphoma
China's National Medical Products Administration (NMPA) has granted conditional approval to tazemetostat (Tazverik) for adult patients with relapsed or refractory EZH2-mutated follicular lymphoma who have received at least two prior systemic therapies.
China Grants Conditional Approval for Tazverik to Treat Relapsed or Refractory Follicular Lymphoma
China's National Medical Products Administration (NMPA) has conditionally approved Tazverik (tazemetostat) for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies.
HUTCHMED Reports 65% Growth in Oncology Products Revenue, Achieves Profitability in 2024
HUTCHMED achieved net income of $37.7 million in 2024, reaching profitability ahead of schedule with strong oncology products revenue growth of 65% to $271.5 million.
Savolitinib Plus TAGRISSO® Shows 56% Response Rate in MET-High Lung Cancer, HUTCHMED Reports
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in patients with EGFRm NSCLC with MET overexpression/amplification who progressed on first-line TAGRISSO®.
Fruquintinib-Sintilimab Combination Meets Primary Endpoint in Phase II/III RCC Trial
The FRUSICA-2 Phase II/III study evaluating fruquintinib plus sintilimab as second-line treatment for advanced renal cell carcinoma has met its primary endpoint of progression-free survival.